Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
0.191 SEK | +0.53% | +6.47% | -22.20% |
02-23 | Abliva AB Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2023 | CI |
2023 | Abliva AB Reaches Patient Enrollment Goal for Wave 1 of the FALCON Study | CI |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registrationEPS Revisions
Annual profits - Rate of surprise
1st Jan change | Capi. | |
---|---|---|
-22.20% | 21.85M | |
+3.91% | 109B | |
+10.87% | 105B | |
-0.03% | 22.25B | |
-13.14% | 22.09B | |
-8.03% | 18.68B | |
-38.36% | 17.58B | |
-10.66% | 16.85B | |
+3.75% | 13.76B | |
+36.70% | 12.46B |
- Stock Market
- Equities
- ABLI Stock
- News Abliva AB
- EU Commission Grants Orphan Drug Designation to Abliva’s Mitochondrial Disease Drug Candidate; Stock Jumps